DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 3 Doug Langa - 3 Wegovy - 2 Jody Dushay - 2 Beth - 2 CNN — Wegovy’s - 1 – - 1 Dr - 1
Top related locs:
North America Novo Washington United States U.S
Top related orgs:
Novo Nordisk - 3 CNN - 2 US Food and Drug Administration - 1 Yale University - 1 Yale New Haven Hospital - 1 Diabetes - 1 ” - 1 CNN Health - 1

Search resuls for: "Doug Langa"


3 mentions found


☆ Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update
  + stars: | 2024-03-08 | by ( Meg Tirrell | ) edition.cnn.com   time to read: +4 min
The label expansion may improve insurance coverage for Wegovy, which costs more than $1,300 per month out of pocket before any discounts. Many insurers, including Medicare, don’t cover drugs for weight loss, leaving patients scrambling to afford them. “This patient population has a higher risk of cardiovascular death, heart attack and stroke,” he added. More studies need to be done to show whether there are heart benefits for people who haven’t had a cardiac event. Wegovy continues to be in shortage, along with other GLP-1 medicines, as drugmakers struggle to keep up with demand.
Persons: CNN — Wegovy’s, –, Dr, Harlan Krumholz, hasn’t, Eli Lilly, Wegovy, John Sharretts, haven’t, it’s, Sanjay Gupta, Jody Dushay, Beth, Dushay, Novo, Doug Langa, ” Organizations: CNN, US Food and Drug Administration, Yale University, Yale New Haven Hospital, Novo Nordisk, Diabetes, ”, CNN Health, Beth Israel Deaconess Medical Center, Harvard Medical School, Novo Nordisk’s, North America Operations
☆ Drugs like Ozempic and Wegovy could strengthen the US economy, Goldman Sachs predicts
  + stars: | 2024-02-27 | by ( Bryan Mena | ) edition.cnn.com   time to read: +4 min
Washington, DC CNN —The US economy is set to reap considerable benefits from Americans taking popular medications used for weight loss, including Ozempic and Wegovy, Goldman Sachs analysts wrote in a recent research report. Originally developed to treat type 2 diabetes, they proved to be highly effective at helping people shed weight in clinical trials. (Ozempic has not been approved for weight loss by regulators, though Wegovy, a similar drug, has.) Goldman Sachs argues that since poor health unambiguously weighs on the economy, improving health outcomes due to GLP-1s could lower costs and boost productivity, shoring up economic output. For some Americans who are obese but don’t have diabetes, obtaining those drugs has become difficult, if not impossible.
Persons: Goldman Sachs, Eli Lilly, Jody Dushay, Beth, Doug Langa, they’ve Organizations: DC CNN, Government, Novo Nordisk, Beth Israel Deaconess Medical, CNN Locations: Washington, United States, North America, Novo
☆ Novo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than $25 a month
  + stars: | 2023-11-02 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Novo Nordisk on Thursday said 80% of U.S. patients with insurance coverage who take its highly popular weight loss treatment Wegovy are paying less than $25 a month for the drug. He estimated that about 50 million Americans with obesity could be eligible for Wegovy coverage under their health plans. Most patients have to take Wegovy for several months to see — and sustain — significant weight loss. Wegovy, for example, leads to 15% weight loss after 68 weeks, according to clinical trials on the drug. But Novo Nordisk is hoping that new data demonstrating the heart health benefits of Wegovy will put more pressure on insurers to cover the medication and similar weight loss treatments.
Persons: Doug Langa, Langa, Eli Lilly, Karsten Munk Knudsen, Wegovy Organizations: Novo Nordisk, balk, Novo Nordisk's, North, Nordisk, CNBC, U.S . Food, Drug Administration, National Institutes of Health Locations: U.S, Novo, North America
0 next >>
Total: 3